KNSA Stock Analysis: Kiniksa Pharmaceuticals | NASDAQ

Biologics, Monoclonal Antibodies, Cardiac Treatments, Anti-Inflammatory Therapies

Total Rating 75

Safety 76

Buy Signal 0.11

Drug Manufacturers - Specialty & Generic
Industry Rotation: +1.6

Market Cap: 6.10B
Avg Turnover: 40.4M

Risk 3d forecast

Volatility42.1%

VaR 5^th Pctl6.93%

VaR vs Median-0.08%

Reward TTM

Sharpe Ratio1.63

Rel. Str. IBD95.4

Rel. Str. Peer Group81.3

Character TTM

Beta-0.177

Beta Downside-0.938

Hurst Exponent0.556

Drawdowns 3y

Max DD34.14%

CAGR/Max DD1.86

CAGR/Mean DD7.20

EPS (Earnings per Share)

Last SUE: 0.00
Qual. Beats: 0

Revenue

Rev. CAGR: 56.94%
Rev. Trend: 100.0%

Last SUE: 2.71
Qual. Beats: 2

Warnings

P/E Ratio 78.9

Seasonal Headwind

Below Avwap Earnings

Tailwinds

Rs Leader

Idiosyncratic Leader

Seasonality 8.3 years of data

Jan +1.1% 6

Feb +1.1% 6

Mar -7.8% 8

Apr +1.7% 9

May +0.4% 14

Jun +5.5% 30

Jul +8.3% 33

Aug -4.2% 26

Sep +2.7% 9

Oct -10.1% 67

Nov +14.3% 48

Dec -7.5% 13

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: KNSA Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) is a London-headquartered biopharmaceutical company that develops and commercializes therapies targeting inflammatory and immune-mediated diseases, primarily in the United States, the United Kingdom, and other international markets. The company was incorporated in 2015 and went public in May 2018.

Its commercial product is ARCALYST, an interleukin-1 cytokine trap approved to treat recurrent pericarditis, a chronic autoinflammatory cardiovascular condition, with ongoing development also directed at cardiac sarcoidosis. Beyond its marketed asset, Kiniksa is advancing a pipeline that includes KPL-387, a fully human monoclonal antibody in Phase 2/3 trials for recurrent pericarditis, and KPL-116, an Fc-modified monoclonal antibody in pre-clinical development. The company was renamed Kiniksa Pharmaceuticals International, plc in June 2024.

As a clinical-stage and commercial-stage biotech, Kiniksa operates under a typical biopharmaceutical business model that relies on a single approved product to fund continued investment in a pipeline of biologic candidates, with revenue concentration risk offset by long patent protections and high development barriers to entry for competitors in biologics-based therapies.

Headlines to Watch Out For

ARCALYST revenue accelerates with cardiac sarcoidosis label expansion
KPL-387 Phase 2/3 data for recurrent pericarditis approaches
Off-label IL-1 inhibitors compete with ARCALYST pricing power

Piotroski VR-10 (Strict) 6.5

Net Income: 80.7m TTM > 0 and > 6% of Revenue
FCF/TA: 0.20 > 0.02 and ΔFCF/TA 10.38 > 1.0
NWC/Revenue: 59.15% < 20% (prev 57.14%; Δ 2.01% < -1%)
CFO/TA 0.21 > 3% & CFO 185.2m > Net Income 80.7m
Net Debt (-517.0m) to EBITDA (112.1m): -4.61 < 3
Current Ratio: 3.90 > 1.5 & < 3
Outstanding Shares: last quarter (83.4m) vs 12m ago 7.00% < -2%
Gross Margin: 54.49% > 18% (prev 53.10%; Δ 1.39% > 0.5%)
Asset Turnover: 108.0% > 50% (prev 80.06%; Δ 27.93% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)

Altman Z'' 5.93

A: 0.56 (Total Current Assets 668.6m - Total Current Liabilities 171.2m) / Total Assets 896.1m
B: -0.46 (Retained Earnings -414.1m / Total Assets 896.1m)
C: 0.14 (EBIT TTM 110.3m / Avg Total Assets 778.6m)
D: 2.70 (Book Value of Equity 654.1m / Total Liabilities 242.0m)
Altman-Z'' = 5.93 = AAA

Beneish M -3.26

DSRI: 0.46 (Receivables 23.5m/31.9m, Revenue 840.8m/529.3m)
GMI: 0.97 (GM 53.10% / 54.49%)
AQI: 0.70 (AQ_t 0.24 / AQ_t-1 0.35)
SGI: 1.59 (Revenue 840.8m / 529.3m)
TATA: -0.12 (NI 80.7m - CFO 185.2m) / TA 896.1m)
Beneish M = -3.26 (Cap -4..+1) = AA

What is the price of KNSA shares?

As of September 25, 2026, the stock is trading at USD 75.34 with a total of 433,360 shares traded. Over the past week, the price has changed by -5.03%, over one month by -5.09%, over three months by +27.41% and over the past year by +108.76%.

Current recommended Stop Loss: 72.00 (which is 4.4% or 1.3 ATR below the current price).

Is KNSA a buy, sell or hold?

Kiniksa Pharmaceuticals has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy KNSA.

StrongBuy: 4
Buy: 2
Hold: 0
Sell: 0
StrongSell: 0

What are the forecasts/targets for the KNSA price?

Analysts Target Price	98	30.1%

Kiniksa Pharmaceuticals (KNSA) - Fundamental Data Overview as of 23 September 2026

Market Cap USD = 6.10b (6.10b USD * 1.0 USD.USD)
P/E Trailing = 78.9192
P/E Forward = 60.241
P/S = 7.2498
P/B = 9.2176
Revenue TTM = 840.8m USD
EBIT TTM = 110.3m USD
EBITDA TTM = 112.1m USD
Long Term Debt = 4.88m USD (estimated: total debt 8.90m - short term 4.01m)
Short Term Debt = 4.01m USD (from shortTermDebt, last quarter)
Debt = 8.90m USD (from shortLongTermDebtTotal, last quarter) (leases 8.90m already included)
Net Debt = -517.0m USD (calculated: Debt 8.90m - CCE 525.9m)
Enterprise Value = 5.58b USD (6.10b + Debt 8.90m - CCE 525.9m)
Interest Coverage Ratio = unknown (Ebit TTM 110.3m / Interest Expense TTM 0.0)
EV/FCF = 30.47x (Enterprise Value 5.58b / FCF TTM 183.1m)
FCF Yield = 3.28% (FCF TTM 183.1m / Enterprise Value 5.58b)
FCF Margin = 21.78% (FCF TTM 183.1m / Revenue TTM 840.8m)
Net Margin = 9.59% (Net Income TTM 80.7m / Revenue TTM 840.8m)
Gross Margin = 54.49% ((Revenue TTM 840.8m - Cost of Revenue TTM 382.7m) / Revenue TTM)
Gross Margin QoQ = 54.17% (prev 55.02%)
Tobins Q-Ratio = 6.23 (Enterprise Value 5.58b / Total Assets 896.1m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 8.90m)
Taxrate = 29.40% (33.6m / 114.3m)
NOPAT = 77.9m (EBIT 110.3m * (1 - 29.40%))
Current Ratio = 3.90 (Total Current Assets 668.6m / Total Current Liabilities 171.2m)
Debt / Equity = 0.01 (Debt 8.90m / totalStockholderEquity, last quarter 654.1m)
Debt / EBITDA = -4.61 (Net Debt -517.0m / EBITDA 112.1m)
Debt / FCF = -2.82 (Net Debt -517.0m / FCF TTM 183.1m)
Total Stockholder Equity = 590.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.36% (Net Income 80.7m / Total Assets 896.1m)
RoE = 13.65% (Net Income TTM 80.7m / Total Stockholder Equity 590.7m)
RoCE = 18.52% (EBIT 110.3m / Capital Employed (Equity 590.7m + L.T.Debt 4.88m))
RoIC = 11.34% (NOPAT 77.9m / Invested Capital 686.8m)
WACC = 5.35% (E(6.10b)/V(6.10b) * Re(5.36%) + D(8.90m)/V(6.10b) * Rd(0.0%) * (1-Tc(0.29)))
Discount Rate = 5.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.89 | Cagr: 7.66%
[DCF] Terminal Value 77.97% ; FCFF base≈136.5m ; Y1≈156.4m ; Y5≈230.2m
[DCF] Fair Price = 82.45 (EV 3.46b - Net Debt -517.0m = Equity 3.98b / Shares 48.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 99.97 | Revenue CAGR: 56.94% | SUE: 2.71 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.32 | Chg30d=-2.33% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=1.16 | Chg30d=-3.54% | Revisions=-17% | GrowthEPS=+54.3% | GrowthRev=+46.7%
EPS next Year (2027-12-31): EPS=1.62 | Chg30d=-7.97% | Revisions=-17% | GrowthEPS=+39.7% | GrowthRev=+22.9%
[Analyst] Revisions Ratio: -15% (up=4, down=6)